EirGenix (Taiwan) Today
| 6589 Stock | TWD 88.60 2.00 2.31% |
Performance4 of 100
| Odds Of DistressLess than 33
|
EirGenix is selling for under 88.60 as of the 23rd of November 2024; that is 2.31% up since the beginning of the trading day. The stock's lowest day price was 88.4. EirGenix has about a 33 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for EirGenix are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of November 2023 and ending today, the 23rd of November 2024. Click here to learn more.
EirGenix Inc. operates as a contract development and manufacturing company worldwide. Its services include cell line development, process development, analytical sciences and quality control, cGMP manufacturing, and antibody drug conjugate. EIRGENIX INC operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange. The company has 304.26 M outstanding shares. More on EirGenix
Moving against EirGenix Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
EirGenix Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. EirGenix's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding EirGenix or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
EirGenix (6589) is traded on Taiwan OTC Exchange in Taiwan and employs 20 people. The company currently falls under 'Large-Cap' category with a current market capitalization of 36.97 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate EirGenix's market, we take the total number of its shares issued and multiply it by EirGenix's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. EirGenix operates under Healthcare sector and is part of Biotechnology industry. The entity has 304.26 M outstanding shares.
EirGenix has accumulated about 626.11 M in cash with (29.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.7.
Check EirGenix Probability Of Bankruptcy
Ownership AllocationEirGenix holds a total of 304.26 Million outstanding shares. EirGenix retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check EirGenix Ownership Details
EirGenix Risk Profiles
Although EirGenix's alpha and beta are two of the key measurements used to evaluate EirGenix's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.18 | |||
| Semi Deviation | 1.38 | |||
| Standard Deviation | 1.7 | |||
| Variance | 2.88 |
EirGenix Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in EirGenix without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
EirGenix Corporate Executives
Elected by the shareholders, the EirGenix's board of directors comprises two types of representatives: EirGenix inside directors who are chosen from within the company, and outside directors, selected externally and held independent of EirGenix. The board's role is to monitor EirGenix's management team and ensure that shareholders' interests are well served. EirGenix's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, EirGenix's outside directors are responsible for providing unbiased perspectives on the board's policies.
| HsiuChuan Yang | Head CFO | Profile | |
| ChihJung Chang | Chief Operating Officer, Chief Manufacturing Officer, Deputy General Manager | Profile |
Additional Tools for EirGenix Stock Analysis
When running EirGenix's price analysis, check to measure EirGenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy EirGenix is operating at the current time. Most of EirGenix's value examination focuses on studying past and present price action to predict the probability of EirGenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move EirGenix's price. Additionally, you may evaluate how the addition of EirGenix to your portfolios can decrease your overall portfolio volatility.